A phase I study of ZX-007, a third generation abuse-deterrent tablet formulation of hydrocodone ER, for the treatment of pain

Trial Profile

A phase I study of ZX-007, a third generation abuse-deterrent tablet formulation of hydrocodone ER, for the treatment of pain

Planning
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2015

At a glance

  • Drugs Hydrocodone (Primary)
  • Indications Pain
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Apr 2015 New trial record
    • 24 Apr 2015 Zogenix plans to submit an NDA for this third-generation product in mid-2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top